More articles from Chemical Therapeutics

MPT0B098, a Novel Microtubule Inhibitor That Destabilizes the Hypoxia-Inducible Factor-1α mRNA through Decreasing Nuclear–Cytoplasmic Translocation of RNA-Binding Protein HuR
Yun-Ching Cheng, Jing-Ping Liou, Ching-Chuan Kuo, Wen-Yang Lai, Kuang-Hsing Shih, Chi-Yen Chang, Wen-Yu Pan, Joseph T. Tseng, Jang-Yang Chang

Molecular Cancer Therapeutics Jul 2013, 12 (7) 1202-1212; DOI: 10.1158/1535-7163.MCT-12-0778
Identification and Characterization of a Small-Molecule Inhibitor of Wnt Signaling in Glioblastoma Cells
Alessandra De Robertis, Silvia Valensin, Marco Rossi, Patrizia Tunici, Margherita Verani, Antonella De Rosa, Cinzia Giordano, Maurizio Varrone, Arianna Nencini, Carmela Pratelli, Tiziana Benicchi, Annette Bakker, Jeffrey Hill, Kanda Sangthongpitag, Vishal Pendharkar, Boping Liu, Fui Mee Ng, Siew Wen Then, Shi Jing Tai, Seong-Moon Cheong, Xi He, Andrea Caricasole, Massimiliano Salerno

Molecular Cancer Therapeutics Jul 2013, 12 (7) 1180-1189; DOI: 10.1158/1535-7163.MCT-12-1176-T
CXCR4-Targeted Therapy Inhibits VEGF Expression and Chondrosarcoma Angiogenesis and Metastasis
Xiaojuan Sun, Cherie Charbonneau, Lei Wei, Wentian Yang, Qian Chen, Richard M. Terek

Molecular Cancer Therapeutics Jul 2013, 12 (7) 1163-1170; DOI: 10.1158/1535-7163.MCT-12-1092
PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer
Katherine T. Ostapoff, Niranjan Awasthi, Bercin Kutluk Cenik, Stefan Hinz, Keith Dredge, Roderich E. Schwarz, Rolf A. Brekken

Molecular Cancer Therapeutics Jul 2013, 12 (7) 1190-1201; DOI: 10.1158/1535-7163.MCT-12-1123
CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
Roberto A. Salas Fragomeni, Hye Won Chung, Yosef Landesman, William Senapedis, Jean-Richard Saint-Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael Kauffman, James C. Cusack

Molecular Cancer Therapeutics Jul 2013, 12 (7) 1171-1179; DOI: 10.1158/1535-7163.MCT-12-1171
Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer
Shili Xu, Fedora Grande, Antonio Garofalo, Nouri Neamati

Molecular Cancer Therapeutics Jun 2013, 12 (6) 937-949; DOI: 10.1158/1535-7163.MCT-12-1082
Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
Jing Wang, Natalie W. Pursell, Maria Elena S. Samson, Ruzanna Atoyan, Anna W. Ma, Abdelkader Selmi, Wanlu Xu, Xiong Cai, Maurizio Voi, Pierre Savagner, Cheng-Jung Lai

Molecular Cancer Therapeutics Jun 2013, 12 (6) 925-936; DOI: 10.1158/1535-7163.MCT-12-1045
The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
Edward B. Garon, Richard S. Finn, Habib Hamidi, Judy Dering, Sharon Pitts, Naeimeh Kamranpour, Amrita J. Desai, Wylie Hosmer, Susan Ide, Emin Avsar, Michael Rugaard Jensen, Cornelia Quadt, Manway Liu, Steven M. Dubinett, Dennis J. Slamon

Molecular Cancer Therapeutics Jun 2013, 12 (6) 890-900; DOI: 10.1158/1535-7163.MCT-12-0998
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Ahrum Min, Seock-Ah Im, Young-Kwang Yoon, Sang-Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang-Phill Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J. O'Connor, Woo-Ho Kim, Yung-Jue Bang

Molecular Cancer Therapeutics Jun 2013, 12 (6) 865-877; DOI: 10.1158/1535-7163.MCT-12-0950
Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
H. Eirik Haarberg, Kim H.T. Paraiso, Elizabeth Wood, Vito W. Rebecca, Vernon K. Sondak, John M. Koomen, Keiran S.M. Smalley

Molecular Cancer Therapeutics Jun 2013, 12 (6) 901-912; DOI: 10.1158/1535-7163.MCT-12-1003

Main menu

User menu

Search

More articles from Chemical Therapeutics

Pages

Articles

Info for

About MCT